Get started
Black Diamond Therapeutics, Inc.Black Diamond Therapeutics, Inc.Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

BDTX chart


Full chart

BDTX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪89.55 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.27 USD
Net income (FY)
‪−69.68 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪43.15 M‬
Beta (1Y)
2.05

Employees


Employees (FY)
24
Change (1Y)
−30 −55.56%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−2.90 M‬ USD

About Black Diamond Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Mark A. Velleca
Website
blackdiamondtherapeutics.com
Headquarters
Cambridge
Founded
2014
FIGI
BBG00MS4Y0W9
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BDTX news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as BDTX.

Frequently Asked Questions


The current price of BDTX is 1.61 USD — it has increased by 1.28% in the past 24 hours. Watch Black Diamond Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Black Diamond Therapeutics, Inc. stocks are traded under the ticker BDTX.
BDTX stock has risen by 12.86% compared to the previous week, the month change is a −9.71% fall, over the last year Black Diamond Therapeutics, Inc. has showed a −68.07% decrease.
We've gathered analysts' opinions on Black Diamond Therapeutics, Inc. future price: according to them, BDTX price has a max estimate of 20.00 USD and a min estimate of 9.00 USD. Watch BDTX chart and read a more detailed Black Diamond Therapeutics, Inc. stock forecast: see what analysts think of Black Diamond Therapeutics, Inc. and suggest that you do with its stocks.
BDTX reached its all-time high on Jun 3, 2020 with the price of 46.25 USD, and its all-time low was 1.18 USD and was reached on Oct 17, 2022. View more price dynamics on BDTX chart.
See other stocks reaching their highest and lowest prices.
BDTX stock is 3.87% volatile and has beta coefficient of 2.05. Track Black Diamond Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Black Diamond Therapeutics, Inc. there?
Today Black Diamond Therapeutics, Inc. has the market capitalization of ‪89.55 M‬, it has increased by 3.60% over the last week.
Yes, you can track Black Diamond Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Black Diamond Therapeutics, Inc. is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
BDTX earnings for the last quarter are −0.28 USD per share, whereas the estimation was −0.31 USD resulting in a 11.02% surprise. The estimated earnings for the next quarter are 0.20 USD per share. See more details about Black Diamond Therapeutics, Inc. earnings.
Black Diamond Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of 0.00 USD. In the next quarter, revenue is expected to reach ‪46.67 M‬ USD.
BDTX net income for the last quarter is ‪−15.98 M‬ USD, while the quarter before that showed ‪−15.56 M‬ USD of net income which accounts for −2.75% change. Track more Black Diamond Therapeutics, Inc. financial stats to get the full picture.
No, BDTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 24, 2025, the company has 24 employees. See our rating of the largest employees — is Black Diamond Therapeutics, Inc. on this list?
Like other stocks, BDTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Black Diamond Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Black Diamond Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Black Diamond Therapeutics, Inc. stock shows the sell signal. See more of Black Diamond Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.